DUXAP8 a Pan-Cancer Prognostic Marker Involved in the Molecular Regulatory Mechanism in Hepatocellular Carcinoma: A Comprehensive Study Based on Data Mining, Bioinformatics, and in vitro Validation

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Chaosen Yue^{1,*}
Chaojie Liang^{2,*}
Pengyang Li³
Lijun Yan¹
Dongxin Zhang¹
Yingchen Xu¹
Zhigang Wei²
Jixiang Wu¹

¹Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China; ²Department of General Surgery, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China; ³Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA

*These authors contributed equally to this work

Correspondence: Jixiang Wu
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing 100730, People's Republic of China
Email trwujixiang2018@126.com

Zhigang Wei
Department of General Surgery, First Hospital/First Clinical Medical College of Shanxi Medical University, No. 85 Jiefangnan Road, Yingze District, Taiyuan, Shanxi 030001, People's Republic of China
Email weizhigang2018@126.com

Background: Double homeobox A pseudogene 8 (*DUXAP8*) has been identified as a key regulator at the posttranscriptional level in various types of cancers. However, whether *DUXAP8* has a role in hepatocellular carcinoma (HCC) progression remains to be determined. Here, we aimed to investigate the potential clinical value of *DUXAP8* as a pan-cancer marker, and its role in HCC development through an integrated analysis strategy and in vitro experimental validation.

Methods: Comprehensive analysis was performed using data mined from public databases to evaluate the expression patterns and clinical value of *DUXAP8* in human pan-cancers. Bioinformatics analysis was performed to investigate the potential biological functions of *DUXAP8* in HCC based on TCGA database. Real-time qPCR analysis was used to examine the expression levels of *DUXAP8* in HCC tissue samples and cell lines. *DUXAP8*-siRNA was used to silence *DUXAP8* in the Hep-G2 cell line to examine the role of *DUXAP8* in HCC cell proliferation and invasion.

Results: *DUXAP8* was significantly upregulated in various types of human cancers and could serve as a potential pan-cancer diagnostic and prognostic biomarker. Bioinformatics analysis suggested that *DUXAP8* might be involved in the regulation of the biological processes of HCC cell cycle, cell division and cell proliferation. Additionally, downregulation of *DUXAP8* inhibited HCC cell proliferation and invasion in vitro.

Conclusion: This study revealed that *DUXAP8* may serve as a potential pan-cancer prognostic and diagnostic marker in humans. In addition, *DUXAP8* promoted HCC cell proliferation and invasion, suggesting that it may represent a novel therapeutic target for HCC.

Keywords: *DUXAP8*, pan-cancer marker, hepatocellular carcinoma

Introduction

Despite the rapid advances in medical science in recent decades, cancer still represents the most significant threat to human health.¹⁻³ Malignant tumors remain one of the leading causes of death worldwide, mainly due to the late diagnosis of most patients who are frequently not diagnosed until advanced stages as well as to the lack of effective therapy.⁴ Accordingly, the identification of novel cancer biomarkers and the understanding of their involvement in the underlying molecular

mechanisms of tumorigenesis and cancer progression are urgent and essential for the development of more effective diagnostic methods and therapeutic strategies.

Pseudogenes have long been considered to be non-functional transcriptional relics of the genome of various organisms.⁵ Approximately 15,000 pseudogenes, including unprocessed and processed pseudogenes, have been identified in the human genome according to the latest annotation of the ENCODE project.⁶ The functional role of pseudogenes remains poorly understood and several studies have suggested that pseudogenes could play key roles in cancer progression by acting as competing endogenous RNAs (ceRNAs) in recent years.^{7,8}

Double homeobox A pseudogene 8 (*DUXAP8*) is a member of the DUXA homeobox gene family. In 2017, Sun et al first determined by bioinformatics analysis that *DUXAP8* was overexpressed in lung cancer tissues and then demonstrated that *DUXAP8* promoted cell invasion and proliferation through epigenetic silencing of *RHOB* and *EGR1* in non-small cell lung cancer.⁹ Recently, pseudogene *DUXAP8* has been shown to be upregulated in multiple cancers and plays critical regulatory roles in cancer progression. For instance, *DUXAP8* was shown to regulate cell growth by epigenetic silencing of *PLEKHO1* expression in gastric cancer.¹⁰ In addition, knockdown of *DUXAP8* inhibited cell proliferation and invasion in esophageal squamous cell cancer.¹¹ Moreover, expression of *DUXAP8* promoted pancreatic carcinoma cell growth by epigenetic silencing of *KLF2* and *CDKN1A*.¹² Also, high levels of *DUXAP8* was associated with poor prognosis in patients with lung,⁹ gastric,¹⁰ esophageal,¹¹ pancreatic,¹² glioma,¹³ and bladder¹⁴ cancers. However, the degree and reliability of the prognostic value of *DUXAP8* in human cancers has not been thoroughly evaluated due to the limited studies and small sample size. Furthermore, the expression pattern and biological function of *DUXAP8* in HCC remain unclear.

In this study, due to the limited published studies on *DUXAP8*, RNA sequencing (RNA-Seq) count matrix and matched clinical data extracted from the Cancer Genome Atlas (TCGA) database were used to evaluate the expression of *DUXAP8* and its clinical significance in human cancers. Additionally, we verified the *DUXAP8* expression levels in 66 HCC samples and corresponding adjacent normal liver tissue samples by polymerase chain reaction (PCR) analysis and explored its biological function in HCC through in vitro cellular function assays.

Materials and Methods

Data Acquisition

Data from TCGA database (<https://cancergenome.nih.gov/>), RNA-Seq count matrices of human pan-cancers were extracted using the R software (<https://www.r-project.org/>). Datasets that lacked sufficient samples or survival information were excluded. Gene symbols corresponding to each Ensembl ID were acquired based on the gene transfer format file (Homo_sapiens.GRCh38.96.chr) using the R software. In addition, studies concerning *DUXAP8* in the PubMed, EMBASE and Web of Science databases were comprehensively evaluated in this study.

DUXAP8 Expression and Its Clinical Value in Human Cancers

Expression levels of *DUXAP8* in various human cancers were acquired from TCGA database to assess the expression patterns of *DUXAP8* in pan-cancers. The area under the curve (AUC), specificity, and sensitivity of each dataset were acquired by receiver operating characteristic (ROC) curve analysis. Then, the pooled AUC was calculated by summary ROC (SROC) curve analysis to evaluate the diagnostic value of *DUXAP8* in pan-cancers. The Deeks' funnel plot asymmetrical test was performed to assess the potential publication bias in the SROC analysis.

The hazard ratio (HR) with 95% confidence interval (CI) was calculated to evaluate the association of *DUXAP8* expression with overall survival (OS) in each study, and the pooled HR was calculated by meta-analysis to assess the prognostic importance of *DUXAP8* in pan-cancers. Potential publication bias was assessed using the funnel plots with Begg's test. High *DUXAP8* expression was considered to be related to poor prognosis if the pooled HR>1 and the 95% CI did not overlap 1.

Tissue Specimens and HCC Cells

A total of 66 pairs of HCC-tissue and adjacent liver-tissue samples were collected from the Department of General Surgery at Beijing Tongren Hospital between 2011 and 2017. No patients received other treatments before sample collection. Written informed consent, which was in accordance with the Declaration of Helsinki, was obtained from each patient. The protocol of this study was approved by the institutional review board of Beijing Tongren Hospital, Capital Medical University.

HCC cell lines (BEL-7404, HEP-G2, BEL-7402, SMMC-7721, HUH-7, and HEP-3B) and the normal

human liver cell line (LO-2) were obtained from the Cell Bank of Shanghai Institute of Biochemistry & Cell Biology (Shanghai, China). All the cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.

Real-Time Quantitative PCR (RT-qPCR) Analysis

Total RNA was extracted from the tissue samples using Trizol (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA). A reverse-transcription kit was used to synthesize cDNA. The real-time PCR analysis was performed using a real-time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Gene expression level was determined by comparing Ct ($2^{-\Delta\Delta CT}$) values.¹⁵

Cell Transfection

Three siRNA sequences (si-DUXAP8-1#: 5'-AAGATAAAGGTGGTTTCCACAAGAA-3'; si-DUXAP8-2#: 5'-GGAAGTCCCAAACCTCCATGATTT-3'; si-DUXAP8-3#: 5'-CAGCATACTTCAAATTCACAGCAAA-3') were designed according to the cDNA sequence of *DUXAP8* obtained from GeneBank. HCC cells were transfected with siRNA using lipofectamine (Invitrogen) according to the manufacturer's instructions. In addition, a negative control sequence (si-NC) was synthesized for use as the negative control group.

Cell Viability and Colony Formation Assays

Cells from si-NC and si-DUXAP8 groups were seeded into 96-well plates. Cells viability was accessed at 24, 48, 72, and 96 h using the Cell Counting Kit 8 (CCK-8) assays according to the manufacturer's instructions (Dojindo Laboratories, Kumamoto, Japan). For the colony formation assay, the colonies containing more than 50 cells were counted two weeks after seeding the cells into 6-well plates.

Transwell Assay and Wound Healing assay

Transwell chambers with Matrigel were used to evaluate cell invasion ability. Briefly, cell suspensions of the si-DUXAP8 and si-NC groups were added to the upper Transwell chambers containing serum-free medium. The corresponding lower chambers containing 10% FBS medium served as a chemo-attractant. Cells that migrated onto the lower surface of the membrane after 24 h incubation were fixed with formaldehyde and stained with hematoxylin for 30 min.

Cells which migrated to the lower compartment of the chamber were counted using a microscope in 5 randomly selected fields. For the wound healing assay, cells from the 2 groups were seeded into 6-well plates. A scratch wound was made in each well by scratching the cell layer once confluence was reached. Cells were cultured in medium after washing away the detached cells with PBS. Photos were captured at 0, 8 and 24 h to determine the number of cells migrating into the scratch wound.

Statistical Analysis

Kaplan-Meier survival analysis and ROC curve analysis were performed using the GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA). Survival data was extracted from the Kaplan-Meier curve using the Engauge Digitizer software if the published article did not provide them, and then the HR was calculated using Tierney's method.¹⁶ Meta-analysis and SROC curve analysis were conducted using the Stata software (College Station, TX, USA). All experiments in the current study were conducted in triplicate, and the results are represented as the mean $\pm$ SD. Comparison among different groups was performed by one-way analysis of variance (ANOVA) test or Student's *t*-test, and $P < 0.05$ indicates statistical significance.

Results

DUXAP8 Was Overexpressed and Had Excellent Clinical Value in Human Cancers

A total of 28 studies including 8301 patients were enrolled in this study. Among them, 17 TCGA datasets contained the expression data of *DUXAP8* in sufficient tumor and normal samples. HRs with 95% CI for OS of cancer patients were calculated based on *DUXAP8* expression and survival information extracted from 22 TCGA datasets. Six published articles detected OS comparisons between patients with high and low expression of *DUXAP8*. Detailed information of the collected studies is shown in [Tables S1](#) and [S2](#).

The data of *DUXAP8* expression in human cancer - tissue samples and normal tissue samples from patients with various types of cancers were extracted from each RNA-Seq count matrix and then log₂-transformed. *DUXAP8* was significantly overexpressed in 15 types of human cancers, as shown in [Figure 1](#). The AUC was obtained by ROC curve analysis for each TCGA dataset

Figure 1 DUXAP8 expression levels in pan-cancers according to TCGA database (* $P < 0.05$).

Abbreviation: TCGA, The Cancer Genome Atlas.

(Table S1) to determine the diagnostic value of *DUXAP8* in each type of cancer. Then, the pooled specificity, sensitivity, and AUC were obtained by SROC curve analysis. As shown in Figure 2A and B, the pooled AUC was 0.82 [0.78–0.85], pooled sensitivity was 0.70 [0.63–0.75], and the pooled specificity was 0.84 [0.76–0.90]. The above results indicated that *DUXAP8* had an excellent diagnostic value in pan-cancers. The results of Deeks' funnel plot asymmetry test indicated that no significant publication bias existed for the studies in this SROC analysis ($P = 0.25$) (Figure 2C).

Next, we calculated the HR of each TCGA dataset based on the *DUXAP8* expression data and matched OS information of the patients. For the published articles that were included in this study, the HR was obtained using the survival data excerpted from the Kaplan–Meier curves. The pooled HR obtained by meta-analysis suggested that *DUXAP8* had an excellent prognostic value in human cancers (pooled HR=1.20[1.06–1.34], $P < 0.01$, random), as shown in Figure 3. No significant publication bias existed for the studies in this meta-analysis according to the Begg's funnel plot test ($P = 0.18$). The results of this

Figure 2 SROC curve analysis according to TCGA database.

Notes: (A) Pooled sensitivity and pooled specificity were calculated to assess the diagnostic value of *DUXAP8* in pan-cancers. (B) The results of pooled AUC (0.82 [0.78–0.85]) indicated that *DUXAP8* has a good diagnostic value in pan-cancers. (C) No publication bias existed in the SROC analysis based on Deeks' funnel plot asymmetrical test ($P=0.25$).

Abbreviations: SROC, summary receiver operating characteristic curve; TCGA, the cancer genome atlas; AUC, area under the curve.

meta-analysis were reliable according to the sensitivity analysis, which indicated that all the datasets were within the 95% CI of the combined analysis.

The above results suggested that *DUXAP8* was up-regulated in human tumor tissues and could be used as a prognostic and diagnostic marker in human cancers.

Figure 3 Pooled HR was calculated to assess the prognostic value of *DUXAP8* in pan-cancers.

Note: Meta-analysis was performed to obtain the pooled HR.

Abbreviation: HR, hazard ratio.

Correlation Between *DUXAP8* Expression and Clinicopathological Characteristics in HCC Patients

Given that the expression pattern and clinical significance of *DUXAP8* in HCC were not yet characterized, we investigated the correlation between the *DUXAP8* expression level of HCC tissue and the clinicopathologic characteristics of HCC patients based on the information extracted from TCGA database. The results revealed that *DUXAP8* was significantly overexpressed in HCC tissue (Figure 4A and B), and *DUXAP8* had excellent diagnostic value in HCC patients, according to the ROC curve analysis (AUC=0.84[0.80–0.88]) (Figure 4C). In addition, a high *DUXAP8* expression level indicated poor OS in HCC patients (Figure 4D). Moreover, *DUXAP8* was significantly overexpressed in patients over 60 years of age (Age $\geq$ 60, $5.61 \pm$

0.15 vs. Age $<$ 60, 4.73 ± 0.18 ; $P < 0.01$), with higher pathological stage (Stage III+IV, 5.67 ± 0.23 vs. Stage I+II, 4.97 ± 0.14 ; $P = 0.04$), and with vascular invasion (Positive, 5.47 ± 0.23 vs. Negative 4.78 ± 0.15 ; $P = 0.03$), as shown in Table 1.

Identification of *DUXAP8* Related Protein-Coding Genes in HCC

To investigate the potential molecular regulatory mechanisms of *DUXAP8* in HCC tumorigenesis, the protein-coding genes whose expression level was closely correlated with that of *DUXAP8* were identified. Two-sided Pearson correlation coefficient analysis and the z-test were performed using the R software based on the gene expression data extracted from TCGA. |Pearson correlations| > 0.50 and z-test $p < 0.001$ were used as cutoff criteria. Ultimately, a total of 177 protein-coding genes were identified as *DUXAP8*-related genes (Table 2).

Figure 4 DUXAP8 expression patterns in HCC according to TCGA database.

Notes: (A) DUXAP8 expression levels in HCC tissues compared with normal liver tissues, according to unpaired student's t-test. (B) DUXAP8 expression level in HCC tissue compared with adjacent liver tissue from the same patient according to paired student's t-test. (C) Significance of DUXAP8 in HCC according to the ROC curve analysis. (D) Overall survival (OS) plots of DUXAP8.

Abbreviations: HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; ROC, receiver operating characteristic curve.

Gene-Annotation and Pathway Enrichment Analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology (GO) annotation enrichment analyses were performed using the DAVID online tool (<https://david.ncifcrf.gov/>) to identify the potential

signaling pathways and biological processes involved in HCC tumorigenesis and progression in which DUXAP8 participates.

As shown in Figure 5A, regarding the GO enrichment analysis, there were 25 significant biological process annotations ($P < 0.01$), which included G1/S and transition of

Table 1 Correlation Between *DUXAP8* Expression and Clinicopathological Characteristics in TCGA

Characteristics		n	DUXAP8 Expression in TCGA Database	
			M ± SD	P-values
Tissues	HCC tissues Adjacent liver tissues	371 50	5.22 ± 0.12 2.47 ± 0.18	<0.01*
Gender	Male Female	250 121	5.27 ± 0.14 5.08 ± 0.21	0.44
Age	≥60 <60	202 169	5.61 ± 0.15 4.73 ± 0.18	<0.01*
Tumor grade	G1+G2 G3+G4	232 134	5.11 ± 0.15 5.37 ± 0.20	0.28
Pathologic stage	I–II III–IV	257 90	4.97 ± 0.14 5.67 ± 0.23	0.04*
Vascular invasion	Negative Positive	206 109	4.78 ± 0.15 5.47 ± 0.23	0.03*
Recurrence	Yes No	95 174	4.97 ± 0.24 5.03 ± 0.16	0.83

Note: *P < 0.05.

Abbreviation: TCGA, the Cancer Genome Atlas.

mitotic cell cycle, cell division, G2/M transition of mitotic cell cycle, cell proliferation, etc. The GO enrichment analysis also revealed that there were 22 significant cellular component terms ($P < 0.01$), which were correlated with condensed chromosome kinetochore, kinetochore, nucleoplasm, centrosome, etc. The GO analysis also revealed 8

significant molecular function terms ($P < 0.01$), associated with protein binding, microtubule motor activity, ATP binding, DNA-dependent ATPase activity, etc. The detailed data are listed in Table 3.

Regarding the KEGG pathway enrichment analysis, there were 5 signaling pathways that were statistically significant ($P < 0.01$), including cell cycle, Fanconi anemia pathway, homologous recombination, oocyte meiosis and progesterone-mediated oocyte maturation (Figure 5B).

DUXAP8 Was Overexpressed in HCC Tissue and Cell Lines

To verify the expression pattern of *DUXAP8* in HCC, qPCR analysis was conducted to determine the expression levels of the 66 pairs of HCC tissue samples. As shown in Figure 6A, *DUXAP8* was significantly overexpressed in HCC tissue, according to the paired Student's *t*-test. Furthermore, high *DUXAP8* expression was significantly associated with poor OS in HCC patients, according to the Kaplan–Meier curve analysis (Figure 6B), which was consistent with the result of the comprehensive analysis based on TCGA database.

In addition, the expression levels of *DUXAP8* in the 6 HCC cell lines were higher than that in the normal liver LO-2 cells (Figure 6C). The transfection of the Hep-G2 cells with three siRNAs using a lentiviral vector system revealed that the siRNA-DUXAP8-3# (5'-CAGCATACTTCAAATTCA CAGCAA-3') had the highest interference efficiency according to qPCR analysis. (Figure 7A), thus it was used in subsequent experiments.

Table 2 *DUXAP8*-Related Protein-Coding Genes in HCC Based on TCGA Database

Pearson correlation > 0.50	MKRN3; FAM133A; COX7B2; COL24A1; CARD18; MAGEA1; MAGEA3; MAGEC2; SSX1; CNTNAP4; MAGEA6; CSMD1; DCAF4L2; CTAG2; SLC6A1; DCAF8L2; GABRA3; PLCB1; PPP4R3C; VCX; MAGEC1; C5orf58; SPDL1; SHCBP1; NAA11; LIN28B; EME1; TRIP13; SLC44A5; RAD54L; TGIF2LX; ZC2HC1A; ZNF883; CIP2A; CDCA8; DDIA5; ZNF257; SYT1; MCM10; FSTL5; PKMYT1; GPR158; CC2D1B; NPFFR2; CEP131; TMEM206; CDC7; P3H1; DEPDC1; IBSP; RFLP4B; KIF4A; RNF220; KIF2C; GTSF1; RHEBL1; ZBTB17; NCAPH; ZNF681; ERCC6L; FADS3; PLK4; CCDC137; SGO2; LYPD8; TRAP1; POLQ; ZFP69B; ANKRD27; CSTF2; ZNF716; PDIA2; RAD51; NUP93; CDC45; ORC6; EXO1; GPM2; C18orf54; NGT1; BUB1; G6PD; PGS1; TRIM45; CDC20; CENPI; AGPAT4; TMEM241; CENPE; CSAG1; FANCD2; ZSCAN20; KPNA2; CCNA2; ANLN; MAGEA12; NEIL3; STIL; STX1A; ZNF99; C5orf34; TTF2; CENPU; SMARCD1; KCNK9; E2F2; DBF4B; RBM19; ABCC5; CLSPN; PIGU; HMMR; TEDC2; NRAS; CENPA; EIF2B5; BUB1B; IGF2BP3; CEP55; MAD2L1; GLMN; CDCA5; DIAPH3; NUF2; DDX53; TTK; STMN1; FANCA; C1orf52; SPATS2; SLC36A1; ZNF43; DLGAP5; TOP2A; CWC27; MELK; ITGB3BP; MED8; PLK1; ORC1; DPH2; NCAPG; SLC38A6; TPGS2; MTFR2; RUVBL1; ZIC2; MARS; SOHLH2; MDGA2; MAGEB6; WRAP73; CKAP2L; CENPK; CCDC88A; FANCB; KIF23; XRCC2; PDE6A; NPC1; ADAMTS20; RRM2; TUBG1; ZNF85; UTP6; ECT2; SGO1; STARD9; PRC1; KIF18B; ZNF730; CDKN2A; KIF18A; FAAP24; DCTN2; DCAF8L1; NDC1
Pearson correlation < -0.50	None

Abbreviations: HCC, hepatocellular carcinoma; TCGA, the cancer genome atlas.

Figure 5 Gene-annotation and pathway enrichment analysis.

Notes: (A) GO enrichment analysis; (B) KEGG pathway enrichment analysis.

Abbreviations: GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Table 3 The GO Analysis of *DUXAP8*-Related Protein-Coding Genes in HCC Based on TCGA Database

GO ID	Term	Count	P-value
Biological process			
GO:0007062	Sister chromatid cohesion	20	5.91×10^{-20}
GO:0051301	Cell division	20	4.13×10^{-10}
GO:0007067	Mitotic nuclear division	16	7.53×10^{-9}
GO:0000281	Mitotic cytokinesis	7	1.99×10^{-7}
GO:0007080	Mitotic metaphase plate congression	7	9.19×10^{-7}
GO:0000082	G1/S transition of mitotic cell cycle	9	4.00×10^{-6}
GO:0007094	Mitotic spindle assembly checkpoint	5	2.79×10^{-5}
GO:0000086	G2/M transition of mitotic cell cycle	9	3.50×10^{-5}
GO:0034080	CENP-A containing nucleosome assembly	6	4.15×10^{-5}
GO:0006281	DNA repair	11	5.63×10^{-5}
GO:0036297	Interstrand cross-link repair	6	7.87×10^{-5}
GO:0007019	Microtubule depolymerization	4	8.33×10^{-5}
GO:0006260	DNA replication	9	8.39×10^{-5}
GO:0007018	Microtubule-based movement	7	9.25×10^{-5}
GO:0007052	Mitotic spindle organization	5	1.47×10^{-4}
GO:0006270	DNA replication initiation	5	1.90×10^{-4}
GO:0000070	Mitotic sister chromatid segregation	4	0.001445018
GO:0019886	Antigen processing and presentation of exogenous peptide antigen via MHC class II	6	0.001486498
GO:0007093	Mitotic cell cycle checkpoint	4	0.00297531
GO:0034501	Protein localization to kinetochore	3	0.003492615
GO:0006312	Mitotic recombination	3	0.005947021
GO:0008283	Cell proliferation	10	0.006165774
GO:0006890	Retrograde vesicle-mediated transport, Golgi to ER	5	0.006535823
GO:0007076	Mitotic chromosome condensation	3	0.007911301
GO:0000910	Cytokinesis	4	0.009338818
Cellular component			
GO:0000777	Condensed chromosome kinetochore	12	2.49×10^{-10}
GO:0000776	Kinetochore	11	2.12×10^{-9}
GO:0005654	Nucleoplasm	52	7.95×10^{-8}
GO:0005813	Centrosome	18	1.99×10^{-7}
GO:0000775	Chromosome, centromeric region	8	6.18×10^{-7}
GO:0005634	Nucleus	76	2.42×10^{-6}
GO:0005871	Kinesin complex	7	6.57×10^{-6}
GO:0030496	Midbody	9	1.76×10^{-5}
GO:0045171	Intercellular bridge	6	3.92×10^{-5}
GO:0000922	Spindle pole	8	4.77×10^{-5}
GO:0005815	Microtubule organizing center	9	5.96×10^{-5}
GO:0005829	Cytosol	48	3.06×10^{-4}
GO:0005814	Centriole	7	4.70×10^{-4}
GO:0005737	Cytoplasm	65	0.001064211
GO:0016020	Membrane	34	0.00122264
GO:0015630	Microtubule cytoskeleton	7	0.001284983
GO:0005874	Microtubule	10	0.001665627
GO:0000940	Condensed chromosome outer kinetochore	3	0.002046274
GO:0005694	Chromosome	6	0.002273943
GO:0005819	Spindle	6	0.004189711
GO:0043240	Fanconi anaemia nuclear complex	3	0.007372095
GO:0005730	Nucleolus	16	0.008077134

(Continued)

Table 3 (Continued).

GO ID	Term	Count	P-value
Molecular function			
GO:0005515	Protein binding	110	2.48×10^{-6}
GO:0003777	Microtubule motor activity	7	9.34×10^{-5}
GO:0005524	ATP binding	29	2.12×10^{-4}
GO:0008017	Microtubule binding	9	6.83×10^{-4}
GO:0010997	Anaphase-promoting complex binding	3	0.001226464
GO:0008094	DNA-dependent ATPase activity	4	0.003097754
GO:0003682	Chromatin binding	11	0.003321884
GO:0003688	DNA replication origin binding	3	0.00436336

Abbreviations: TCGA, the cancer genome atlas; GO, gene ontology; HCC, hepatocellular carcinoma.

Effects of *DUXAP8* Expression on HCC Cells Proliferation and Invasion

Cell viability in the *DUXAP8* knockdown group was significantly inhibited compared with that in the si-NC group according to the growth curves obtained with the CCK-8 assay (Figure 7B). Additionally, according to the colony formation assay, HCC cells in the si-*DUXAP8* group produced fewer colonies than those in the negative control group (Figure 7C).

The results of the Transwell assay suggested that downregulation of *DUXAP8* inhibited the invasion ability of HCC cells (Figure 7D). The wound healing assay also revealed that the migration ability of HCC cells in the si-*DUXAP8* group was reduced compared with that in the si-NC group (Figure 7E).

The results of the in vitro cellular function assays described above suggested that overexpression of *DUXAP8* in HCC promoted cell proliferation and invasion.

Discussion

As a result of the development of next-generation sequencing technology, the integrated analysis through data mining, bioinformatics analysis, and meta-analysis has become one of the most powerful methods in cancer research.¹⁷ For example, Zhang et al found that the lncRNA MIR22HG could act as a cancer suppressor in HCC based on data extracted from TCGA portal.¹⁸ In addition, Ge et al showed that LINC00996 is significantly decreased in colorectal cancer tissues and the depletion of LINC00996 is associated with a poor outcome in colorectal cancer patients according to a meta-analysis using data extracted from the Gene Expression Omnibus (GEO) and TCGA databases.¹⁹

In our previous research, we used an integrated analysis approach based on the microarray data from the GEO and TCGA databases and found that *DUXAP10*, which is another member of the DUXA homeobox gene family, could act as a potential marker in pan-cancers.²⁰ Additionally, we also

Figure 6 *DUXAP8* expression pattern in HCC was verified by qPCR analysis.

Notes: (A) *DUXAP8* expression levels in 66 pairs of HCC tissue and adjacent normal liver tissue samples. (B) Overall survival (OS) plots of *DUXAP8* based on the 66 HCC patients' clinical information. (C) *DUXAP8* expression levels in normal liver cells and 6 HCC cell lines.

Abbreviation: HCC, hepatocellular carcinoma.

Figure 7 Effects of *DUXAP8* on HCC cell proliferation and invasion.

Notes: (A) Interference efficiency of the 3 si-RNAs in Hep-G2 cells. (B, C) Downregulation of *DUXAP8* inhibited HCC cell proliferation and viability according to the CCK-8 assay and colony formation assay, respectively. (D, E) Invasion and migration ability of HCC cells was decreased after *DUXAP8* knockdown according to the Transwell assay and wound healing assay (* $P < 0.05$).

Abbreviations: HCC, hepatocellular carcinoma; CCK-8, Cell Counting Kit-8.

showed that *DUXAP10* could regulate cell growth by activating p-AKT in HCC.²¹ After comprehensively searching the studies on *DUXAP8*, we only found a few published articles in electronic databases. Therefore, we decided to mine the expression data of *DUXAP8* from public databases, including TCGA and GEO.

Although, *DUXAP8* has been identified in previous studies as an aberrantly expressed gene in lung cancer and gastric cancer by bioinformatics analysis based on GEO datasets,^{9,10} we could not find any data on *DUXAP8* expression in human cancers from the GEO database, which might be due to the update of probe annotation files. Nevertheless, we successfully extracted the expression information of *DUXAP8* from TCGA database. Comprehensive analysis including data mining, OS analysis, ROC curve analysis, SROC curve analysis, and meta-analysis were performed in this study, and the results revealed that *DUXAP8* was over-expressed in human cancers tissue samples and had both excellent diagnostic and prognostic values in human cancers.

We also found that the *DUXAP8* expression level in HCC tissue was significantly upregulated compared with that in adjacent normal liver tissue ($\log_2FC > 1$ and $P < 0.01$) based on the data extracted from TCGA. Also, high *DUXAP8* expression was highly related to poor OS in HCC ($P < 0.01$), and had excellent diagnostic value ($AUC = 0.84$, 95% CI 0.80–0.88) in HCC according to the ROC curve analysis. Moreover, high *DUXAP8* levels were detected in HCC patients with vascular invasion or high pathologic stage according to our analysis. However, to date, no study has been reported on the roles of *DUXAP8* in HCC tumorigenesis and progression. Accordingly, we identified the *DUXAP8* related protein-coding genes to investigate the potential biological process and signaling pathway in which *DUXAP8* is involved. The results of the GO and KEGG pathway enrichment analysis suggested that *DUXAP8*-related genes were most significantly involved in the biological processes of cell division, cell cycle, etc. Also, according to the above results, we decided to experimentally examine the roles of *DUXAP8* in HCC. The results of the qPCR analysis and in vitro cell function assays showed that *DUXAP8* was upregulated in HCC tissue, and its down-regulation inhibited HCC cell proliferation and invasion.

This study had a number of limitations that should be discussed. First, no clinicopathological characteristics were closely related with the *DUXAP8* expression levels in the 66 HCC tissue samples that were collected in this study, which might be explained by the limited sample size. Second, the signaling pathways through which *DUXAP8* might exert its

regulatory effect on HCC progression were not explored in the current study. Thus, undoubtedly, this issue needs to be addressed through further investigation and verification.

Conclusions

To summarize, this study revealed that *DUXAP8* was over-expressed in pan-cancers and could serve as a potential prognostic and diagnostic marker for cancer patients. In addition, we verified the *DUXAP8* expression pattern in HCC and showed that *DUXAP8* regulated HCC cell growth. To the best of our knowledge, this study is the first investigation of the regulatory roles of *DUXAP8* in HCC and may contribute to the development of novel diagnosis markers and therapeutic approach for HCC.

Acknowledgments

This work was supported by Leader of the First Hospital of Shanxi Medical University (YD1607), Scientific Research Project Plan of Shanxi Provincial Health Planning Commission (2014029), Project Letter of Fostering Team for Precision Medical Key Innovation in the First Hospital of Shanxi Medical University (YT1603), and Shanxi Medical University Doctor's Startup Fund Project (XD1802).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7–30. doi:10.3322/caac.21442
2. Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer statistics for hispanics/ latinos, 2018. *CA Cancer J Clin*. 2018;68(6):425–445. doi:10.3322/caac.21494
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115–132. doi:10.3322/caac.21338
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
5. Proudfoot N. Pseudogenes. *Nature*. 1980;286(5776):840–841. doi:10.1038/286840a0
6. Frankish A, Harrow J. GENCODE pseudogenes. *Methods Mol Biol*. 2014;1167:129–155. doi:10.1007/978-1-4939-0835-6_10
7. Wang L, Guo ZY, Zhang R, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. *Carcinogenesis*. 2013;34(8):1773–1781. doi:10.1093/carcin/bgt139
8. An Y, Furber KL, Ji S. Pseudogenes regulate parental gene expression via ceRNA network. *J Cell Mol Med*. 2017;21(1):185–192. doi:10.1111/jcmm.12952
9. Sun M, Nie FQ, Zang C, et al. The pseudogene DUXAP8 promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB. *Mol Ther*. 2017;25(3):739–751. doi:10.1016/j.ymthe.2016.12.018

10. Ma HW, Xie M, Sun M, et al. The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression. *Oncotarget*. 2017;8(32):52211–52224. doi:10.18632/oncotarget.11075
11. Xu LJ, Yu XJ, Wei B, et al. Long non-coding RNA DUXAP8 regulates proliferation and invasion of esophageal squamous cell cancer. *Eur Rev Med Pharmacol Sci*. 2018;22(9):2646–2652. doi:10.26355/eurrev_201805_14959
12. Lian Y, Yang J, Lian Y, Xiao C, Hu X, Xu H. DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2. *Cancer Commun (Lond)*. 2018;38(1):64. doi:10.1186/s40880-018-0333-9
13. Zhao X, Hao S, Wang M, Xing D, Wang C. Knockdown of pseudogene DUXAP8 expression in glioma suppresses tumor cell proliferation. *Oncol Lett*. 2019;17(3):3511–3516. doi:10.3892/ol.2019.9994
14. Lin MG, Hong YK, Zhang Y, Lin BB, He XJ. Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN. *Eur Rev Med Pharmacol Sci*. 2018;22(11):3370–3377. doi:10.26355/eurrev_201806_15158
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
16. Ge H, Liang C, Ren S, Yue C, Wu J. Prognostic value of DcR3 in solid tumors: a meta-analysis. *Clin Chim Acta*. 2018;481:126–131. doi:10.1016/j.cca.2018.02.038
17. Yue C, Ren Y, Ge H, et al. Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. *Onco Targets Ther*. 2019;12:561–576. doi:10.2147/OTT.S188913
18. Zhang DY, Zou XJ, Cao CH, et al. Identification and functional characterization of long non-coding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma. *Theranostics*. 2018;8(14):3751–3765. doi:10.7150/thno.22493
19. Ge H, Yan Y, Wu D, Huang Y, Tian F. Potential role of LINC00996 in colorectal cancer: a study based on data mining and bioinformatics. *Onco Targets Ther*. 2018;11:4845–4855. doi:10.2147/OTT.S173225
20. Yue C, Ren Y, Ge H, et al. Pseudogene DUXAP10 can be used as a diagnostic and prognostic biomarker in human cancers. *J Cell Physiol*. 2019;234(12):23685–23694. doi:10.1002/jcp.28937
21. Yue C, Liang C, Ge H, et al. Pseudogene DUXAP10 acts as a diagnostic and prognostic marker and promotes cell proliferation by activating PI3K/AKT pathway in hepatocellular carcinoma. *Onco Targets Ther*. 2019;12:4555–4566. doi:10.2147/OTT.S210623

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>